The Ohio Board of Pharmacy recently revoked the licenses of four Ohio medical spas, with concerns over the sourcing and ...

Last year, more than 16 million people googled 'semaglutide' - sold under the brand names Wegovy and Ozempic - as demand for ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

You’ve probably been there — staring at another diet plan, another gym ad, another promise of results. And if you’ve ever ...

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...